DE69435021D1 - Kombination eines Angiotensin-II antagonistisch wirkenden Benzimidazols mit einem Diuretikum - Google Patents
Kombination eines Angiotensin-II antagonistisch wirkenden Benzimidazols mit einem DiuretikumInfo
- Publication number
- DE69435021D1 DE69435021D1 DE69435021T DE69435021T DE69435021D1 DE 69435021 D1 DE69435021 D1 DE 69435021D1 DE 69435021 T DE69435021 T DE 69435021T DE 69435021 T DE69435021 T DE 69435021T DE 69435021 D1 DE69435021 D1 DE 69435021D1
- Authority
- DE
- Germany
- Prior art keywords
- sup
- group
- angiotensin
- compound
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000001882 diuretic effect Effects 0.000 title abstract 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 title 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 title 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 title 1
- 239000002934 diuretic Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 102000005862 Angiotensin II Human genes 0.000 abstract 2
- 101800000733 Angiotensin-2 Proteins 0.000 abstract 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract 2
- 229950006323 angiotensin ii Drugs 0.000 abstract 2
- 150000001450 anions Chemical class 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 230000002213 calciumantagonistic effect Effects 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP13552493 | 1993-06-07 | ||
JP13552493 | 1993-06-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69435021D1 true DE69435021D1 (de) | 2007-10-18 |
DE69435021T2 DE69435021T2 (de) | 2008-05-29 |
Family
ID=15153791
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69435022T Expired - Lifetime DE69435022T2 (de) | 1993-06-07 | 1994-06-07 | Kombination von Angiotensin-II antagonistisch wirkenden Benzimidazolen mit Diuretika |
DE69432644T Expired - Lifetime DE69432644T2 (de) | 1993-06-07 | 1994-06-07 | Kombination eines Angiotensin-II antagonistisch wirkendes Benzimidazols mit ein Diuretikum |
DE69435021T Expired - Lifetime DE69435021T2 (de) | 1993-06-07 | 1994-06-07 | Kombination eines Angiotensin-II antagonistisch wirkenden Benzimidazols mit einem Diuretikum |
DE69434560T Expired - Lifetime DE69434560T2 (de) | 1993-06-07 | 1994-06-07 | Kombination eines Angiotensin-II antagonistisch wirkenden Benzimidazols mit Manidipin zur Behandlung von Bluthochdruck |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69435022T Expired - Lifetime DE69435022T2 (de) | 1993-06-07 | 1994-06-07 | Kombination von Angiotensin-II antagonistisch wirkenden Benzimidazolen mit Diuretika |
DE69432644T Expired - Lifetime DE69432644T2 (de) | 1993-06-07 | 1994-06-07 | Kombination eines Angiotensin-II antagonistisch wirkendes Benzimidazols mit ein Diuretikum |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69434560T Expired - Lifetime DE69434560T2 (de) | 1993-06-07 | 1994-06-07 | Kombination eines Angiotensin-II antagonistisch wirkenden Benzimidazols mit Manidipin zur Behandlung von Bluthochdruck |
Country Status (9)
Country | Link |
---|---|
EP (6) | EP2277520A3 (de) |
AT (4) | ATE239471T1 (de) |
CA (1) | CA2125251C (de) |
CY (1) | CY2370B1 (de) |
DE (4) | DE69435022T2 (de) |
DK (1) | DK0753301T3 (de) |
ES (1) | ES2193217T3 (de) |
PT (1) | PT753301E (de) |
SG (1) | SG45336A1 (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995033456A2 (en) * | 1994-06-07 | 1995-12-14 | Telor Ophthalmic Pharmaceuticals, Inc. | Reducing intraocular pressure using aryloxy- and aryl-acetic acids |
US6228873B1 (en) | 1994-12-09 | 2001-05-08 | The Regents Of The University Of California | Method for enhancing outflow of aqueous humor in treatment of glaucoma |
US5763491A (en) * | 1994-12-09 | 1998-06-09 | The Regents Of The University Of California | Method for enhancing outflow of aqueous humor in treatment of glaucoma |
WO1996018386A1 (en) * | 1994-12-14 | 1996-06-20 | Enbalt Trading Limited | Pharmaceutical tablet formulations for direct compression |
EP0831911B1 (de) * | 1995-06-07 | 2002-04-17 | G.D. Searle & Co. | Kombinationstherapie zur behandlung des kongestiven herzversagens mit spironolacton und angiotensin ii-antagonist |
WO1996040256A1 (en) * | 1995-06-07 | 1996-12-19 | G.D. Searle & Co. | Method to treat cardiofibrosis with a combination of an angiotensin ii antagonist and spironolactone |
PT831910E (pt) * | 1995-06-07 | 2002-05-31 | Searle & Co | Terapia de combinacao a base de um antagonista epoxi-esteroidal de aldosterona e um antagonista de angiotensina ii para o tratamento de ataque cardiaco congestivo |
KR19990087076A (ko) * | 1996-04-05 | 1999-12-15 | 다께다 구니오 | 안지오텐신 ⅱ 및 길항 활성을 갖는 화합물을 함유하는 약제학적 배합물 |
WO1999012534A1 (fr) * | 1997-09-10 | 1999-03-18 | Ono Pharmaceutical Co., Ltd. | Regulateurs des recepteurs actives par le proliferateur des peroxisomes |
SG142116A1 (en) * | 1998-07-10 | 2008-05-28 | Novartis Ag | Antihypersensitive combination of valsartan and calcium channel blocker |
JP4000505B2 (ja) * | 1999-12-01 | 2007-10-31 | 第一三共株式会社 | 緑内障を治療するための併用剤 |
AU2001227084A1 (en) * | 2000-01-25 | 2001-08-07 | Japan Tobacco Inc. | N-arylhydrazide compounds and use thereof as drugs |
CA2426674A1 (en) * | 2000-10-25 | 2002-05-02 | Takeda Chemical Industries, Ltd. | Agent for preventing or treating portal hypertension |
AU2002226365A1 (en) * | 2000-12-01 | 2002-06-11 | Novartis Ag | Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction |
CA2468827A1 (en) * | 2001-12-03 | 2003-06-12 | Takeda Chemical Industries, Ltd. | Insulin resistance improving agents |
IL162475A0 (en) | 2001-12-12 | 2005-11-20 | Pharmacia Corp | Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists |
EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
KR101194453B1 (ko) * | 2003-01-31 | 2012-10-24 | 다이이찌 산쿄 가부시키가이샤 | 동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약 |
ES2334029T3 (es) | 2003-05-15 | 2010-03-04 | Roskamp Research Llc | Procedimiento para producir medicamentos para reducir la deposicion de amiloide, la neurotoxicidad de amiloide y la microgliosis. |
GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
DK2214666T3 (da) | 2007-10-05 | 2014-01-27 | Alzheimer S Inst Of America Inc | Fremgangsmåde til reducering af amyloid-afsætning, amyloid-neurotoksicitet og mikrogliose med (-)-nilvadipin-enantiomer |
BRPI0916847A2 (pt) | 2008-07-31 | 2016-02-10 | Takeda Pharmaceutical | preparação sólida, e, métodos para estabilizar um composto e para melhorar a propriedade de dissolução de um composto. |
AR073380A1 (es) | 2008-09-25 | 2010-11-03 | Takeda Pharmaceutical | Composicion farmaceutica solida. comprimido multicapa |
DE102008059206A1 (de) | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
WO2010075347A2 (en) * | 2008-12-23 | 2010-07-01 | Takeda Pharmaceutical Company Limited | Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone |
MX2011011011A (es) * | 2009-04-30 | 2011-11-02 | Takeda Pharmaceutical | Preparacion solida. |
TR201004754A1 (tr) * | 2010-06-11 | 2012-01-23 | Sanovel �La� San. Ve T�C. A.�. | Yeni Farmasötik Kombinasyonlar |
KR20150007297A (ko) | 2012-05-07 | 2015-01-20 | 바이엘 파마 악티엔게젤샤프트 | 니페디핀 및 칸데사르탄 실렉세틸을 포함하는 제약 투여 형태의 제조 방법 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2016710A1 (en) * | 1989-05-15 | 1990-11-15 | Prasun K. Chakravarty | Substituted benzimidazoles as angiotensin ii antagonists |
IL95975A (en) | 1989-10-24 | 1997-06-10 | Takeda Chemical Industries Ltd | N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them |
US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
ATE171177T1 (de) * | 1990-06-08 | 1998-10-15 | Hoechst Marion Roussel Inc | Benzimidazol-derivate, verfahren und zwischenprodukte zu ihrer herstellung, ihre anwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen |
AU656551B2 (en) * | 1990-12-14 | 1995-02-09 | Smithkline Beecham Corporation | Angiotensin II receptor blocking compositions |
FR2673427B1 (fr) * | 1991-03-01 | 1993-06-18 | Sanofi Elf | Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant. |
IL102183A (en) | 1991-06-27 | 1999-11-30 | Takeda Chemical Industries Ltd | The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them |
TW300219B (de) * | 1991-09-14 | 1997-03-11 | Hoechst Ag | |
TW284688B (de) * | 1991-11-20 | 1996-09-01 | Takeda Pharm Industry Co Ltd | |
GB2270841A (en) * | 1992-09-09 | 1994-03-30 | Merck & Co Inc | Compositions for Treating vascular restenosis |
AU5449194A (en) * | 1992-10-26 | 1994-05-24 | Merck & Co., Inc. | Combinations of angiotensin-ii receptor antagonists and diuretics |
CA2181461A1 (en) * | 1994-02-08 | 1995-08-17 | Alica Huxley | Treatment of normotensive glaucoma with angiotensin ii antagonists |
-
1994
- 1994-06-06 CA CA002125251A patent/CA2125251C/en not_active Expired - Lifetime
- 1994-06-07 EP EP10178599A patent/EP2277520A3/de not_active Withdrawn
- 1994-06-07 EP EP94108687A patent/EP0628313B1/de not_active Expired - Lifetime
- 1994-06-07 EP EP03001570A patent/EP1306089B1/de not_active Expired - Lifetime
- 1994-06-07 DE DE69435022T patent/DE69435022T2/de not_active Expired - Lifetime
- 1994-06-07 DE DE69432644T patent/DE69432644T2/de not_active Expired - Lifetime
- 1994-06-07 EP EP07014995A patent/EP1844774A3/de not_active Ceased
- 1994-06-07 ES ES96115146T patent/ES2193217T3/es not_active Expired - Lifetime
- 1994-06-07 EP EP03001569A patent/EP1306088B1/de not_active Expired - Lifetime
- 1994-06-07 EP EP96115146A patent/EP0753301B1/de not_active Revoked
- 1994-06-07 AT AT96115146T patent/ATE239471T1/de active
- 1994-06-07 DE DE69435021T patent/DE69435021T2/de not_active Expired - Lifetime
- 1994-06-07 AT AT94108687T patent/ATE311188T1/de not_active IP Right Cessation
- 1994-06-07 AT AT03001570T patent/ATE372116T1/de not_active IP Right Cessation
- 1994-06-07 PT PT96115146T patent/PT753301E/pt unknown
- 1994-06-07 SG SG1996003825A patent/SG45336A1/en unknown
- 1994-06-07 DK DK96115146T patent/DK0753301T3/da active
- 1994-06-07 AT AT03001569T patent/ATE372115T1/de not_active IP Right Cessation
- 1994-06-07 DE DE69434560T patent/DE69434560T2/de not_active Expired - Lifetime
-
2003
- 2003-08-04 CY CY0300054A patent/CY2370B1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP1306089A1 (de) | 2003-05-02 |
ATE372116T1 (de) | 2007-09-15 |
DE69434560T2 (de) | 2006-06-08 |
DE69432644D1 (de) | 2003-06-12 |
EP2277520A2 (de) | 2011-01-26 |
CA2125251A1 (en) | 1994-12-08 |
DE69432644T2 (de) | 2003-11-27 |
ATE311188T1 (de) | 2005-12-15 |
EP1844774A2 (de) | 2007-10-17 |
CY2370B1 (en) | 2004-06-04 |
SG45336A1 (en) | 1998-01-16 |
ATE372115T1 (de) | 2007-09-15 |
DE69434560D1 (de) | 2006-01-05 |
EP0753301B1 (de) | 2003-05-07 |
EP2277520A3 (de) | 2011-08-24 |
EP1306089B1 (de) | 2007-09-05 |
EP1844774A3 (de) | 2008-08-20 |
DK0753301T3 (da) | 2003-07-21 |
ES2193217T3 (es) | 2003-11-01 |
ATE239471T1 (de) | 2003-05-15 |
DE69435022D1 (de) | 2007-10-18 |
EP0753301A1 (de) | 1997-01-15 |
EP0628313B1 (de) | 2005-11-30 |
EP1306088B1 (de) | 2007-09-05 |
DE69435022T2 (de) | 2008-05-29 |
PT753301E (pt) | 2003-08-29 |
CA2125251C (en) | 2005-04-26 |
EP1306088A1 (de) | 2003-05-02 |
DE69435021T2 (de) | 2008-05-29 |
EP0628313A1 (de) | 1994-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69435021D1 (de) | Kombination eines Angiotensin-II antagonistisch wirkenden Benzimidazols mit einem Diuretikum | |
ES2065182T3 (es) | Derivados de fenilamidinas utiles como inhibidores de la agregacion de plaquetas. | |
IL96486A0 (en) | Tricyclic compounds,their preparation and pharmaceutical compositions containing them | |
EA200000391A1 (ru) | Производные тиенопиримидина и тиенопиридина, полезные в качестве противораковых агентов | |
ES2120728T3 (es) | Inhibidores de la agregacion de plaquetas. | |
ATE142641T1 (de) | Neue peptid-verbindungen und verfahren zur herstellung davon | |
GR3033862T3 (en) | Angiotensin ii antagonists as a prophylactic or therapeutic drug for renal diseases. | |
ES2110115T3 (es) | Inhibidores de la agregacion de plaquetas. | |
FI935800A0 (fi) | Antidepressiva och mot Parkisons sjukdom verksamma foereningar | |
DK0804418T3 (da) | Platelataggregationshæmmere | |
KR970703301A (ko) | 신규 디아미노메틸리덴 유도체(novel diamincmethylidene derivative) | |
NO934760L (no) | Arylsubstituerte heterosykliske forbindelser | |
DK0604355T3 (da) | Arylsubstituerede heterocykliske forbindelser |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |